Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.

ConditionAcute Myeloid Leukemia

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorUniversity of Freiburg

About this trial

The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements

Hematological relapse after allo-HCT

18 years or older

Disqualifiers

no signed informed consent

Trial population

Patients with AML with NPM1 mutations or KMT2A rearrangements that experience a hematological relapse after allo-HCT

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

20 Participants

are grouped into 1 trial group

Group A: AML with NPM1 mutations or KMT2A rearrangements

Trial outcomes

Primary outcomes

Correlative biomarker

HERV expression by AML cells

Time frame

1 year

Biomarkers will be correlated with survival and leukemia response

The biomarkers HERV, HLA class I and II, T cell phenotype

Time frame

may 2026 till may 2027

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Freiburg

Lead sponsor

Source ClinicalTrials.gov

Apply now